drugset / Trial / NCT00311636

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

NCT00311636

Phase 3 Completed 280 enrolled Gruppo Italiano Mammella (GIM)
RandomizedOpen-labelSupportive care

Summary

RATIONALE: Chemotherapy may cause early menopause in premenopausal women. Triptorelin may prevent this from happening. PURPOSE: This randomized phase III trial is studying triptorelin to see how well it works in preventing early menopause in premenopausal women who are receiving chemotherapy for stage I, stage II, or stage III breast cancer that has been removed by surgery.

Timeline

Start
2003-09
Primary completion
2008-01
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Triptorelin Other / unclassified 3.75 mg Intramuscular
Background Cyclophosphamide Other / unclassified
Background Docetaxel Small molecule
Background Doxorubicin Other / unclassified
Background Epirubicin Small molecule
Background Methotrexate Small molecule
Background Paclitaxel Small molecule
Background fluorouracil Small molecule

Indications